Atacicept is a biological drug that targets and inhibits the activity of B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), proteins that are crucial in the regulation of B-cell activity and antibody production. It is currently under investigation for its potential as a treatment for autoimmune diseases, particularly systemic lupus erythematosus and rheumatoid arthritis, where the overactivity of B-cells is implicated in the disease progression.
Used in Pharmaceutical Industry:
Atacicept is used as a therapeutic agent for the treatment of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. It functions by suppressing excessive B-cell activity, which is a contributing factor in these conditions, thereby potentially reducing disease activity and improving patient outcomes.
Used in Clinical Research:
Atacicept is utilized in clinical trials to evaluate its safety, efficacy, and optimal dosage for long-term use in managing autoimmune diseases. The results from early clinical trials have been promising, indicating its potential to effectively manage B-cell activity and disease symptoms in affected patients. Further research is necessary to confirm its benefits and establish its place in the treatment paradigm for the specified conditions.
Used in Pharmaceutical Industry:
Atacicept is used as a therapeutic agent for the treatment of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. It functions by suppressing excessive B-cell activity, which is a contributing factor in these conditions, thereby potentially reducing disease activity and improving patient outcomes.
Used in Clinical Research:
Atacicept is utilized in clinical trials to evaluate its safety, efficacy, and optimal dosage for long-term use in managing autoimmune diseases. The results from early clinical trials have been promising, indicating its potential to effectively manage B-cell activity and disease symptoms in affected patients. Further research is necessary to confirm its benefits and establish its place in the treatment paradigm for the specified conditions.
845264-92-8
Post Buying Request-
-
Basic information
- Product Name: Atacicept
- Synonyms: ATACICEPT;Unii-K3D9A0icq3
- CAS NO:845264-92-8
- Molecular Formula:
- Molecular Weight: 0
- EINECS: N/A
- Product Categories: N/A
-
Chemical Properties
- Melting Point: N/A
- Boiling Point: N/A
- Flash Point: N/A
- Appearance: /
- Density: N/A
- Refractive Index: N/A
- Storage Temp.: N/A
- Solubility: N/A
- CAS DataBase Reference: Atacicept(CAS DataBase Reference)
- NIST Chemistry Reference: Atacicept(845264-92-8)
- EPA Substance Registry System: Atacicept(845264-92-8)
-
Safety Data
- Hazard Codes: N/A
- Statements: N/A
- Safety Statements: N/A
- WGK Germany:
- RTECS:
- HazardClass: N/A
- PackingGroup: N/A
- Hazardous Substances Data: 845264-92-8(Hazardous Substances Data)
845264-92-8 Suppliers
Recommended suppliers
845264-92-8 Usage
Check Digit Verification of cas no
The CAS Registry Mumber 845264-92-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,2,6 and 4 respectively; the second part has 2 digits, 9 and 2 respectively.Calculate Digit Verification of CAS Registry Number 845264-92:
(8*8)+(7*4)+(6*5)+(5*2)+(4*6)+(3*4)+(2*9)+(1*2)=188
188 % 10 = 8
So 845264-92-8 is a valid CAS Registry Number.
845264-92-8Upstream product
845264-92-8Downstream Products
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 845264-92-8
Atacicept
